Journal article
Obesity, aspirin, and risk of colorectal cancer in carriers of hereditary colorectal cancer: A prospective investigation in the CAPP2 study
M Movahedi, DT Bishop, F Macrae, JP Mecklin, G Moeslein, S Olschwang, D Eccles, DG Evans, ER Maher, L Bertario, ML Bisgaard, MG Dunlop, JWC Ho, SV Hodgson, A Lindblom, J Lubinski, PJ Morrison, V Murday, RS Ramesar, L Side Show all
Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2015
Abstract
Purpose: In the general population, increased adiposity is a significant risk factor for colorectal cancer (CRC), but whether obesity has similar effects in those with hereditary CRC is uncertain. This prospective study investigated the association between body mass index and cancer risk in patients with Lynch syndrome (LS). Patients and Methods: Participants with LS were recruited to the CAPP2 study, in which they were randomly assigned to receive aspirin 600 mg per day or aspirin placebo, plus resistant starch 30 g per day or starch placebo (2×2 factorial design). Mean intervention period was 25.0 months, and mean follow-up was 55.7 months. Results: During follow-up, 55 of 937 participants..
View full abstractGrants
Awarded by Medical Research Council
Funding Acknowledgements
Original intervention study was supported by grants from Medical Research Council (No. G0100496), Cancer Research UK (Nos. C1297/A5013 and C588/A4994), European Union (No. PL96/3694), Cancer Council Victoria (Australia), Technology and Human Resources for Industry Programme-South Africa, Sigrid Juselius Foundation, and Finnish Cancer Foundation. After completion of study design and choice of interventions, Bayer and National Starch and Chemical provided free interventions (active agent and matched placebo), including cost of packaging, and made donations to Newcastle University to help cover cost of administration and distribution of intervention agents. CAPP2 (Current Controlled Trials No. ISRCTN59521990) was academic collaboration.